MX2018012439A - Composiciones y metodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotinico. - Google Patents

Composiciones y metodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotinico.

Info

Publication number
MX2018012439A
MX2018012439A MX2018012439A MX2018012439A MX2018012439A MX 2018012439 A MX2018012439 A MX 2018012439A MX 2018012439 A MX2018012439 A MX 2018012439A MX 2018012439 A MX2018012439 A MX 2018012439A MX 2018012439 A MX2018012439 A MX 2018012439A
Authority
MX
Mexico
Prior art keywords
methods
acetylcholine receptor
nicotinic acetylcholine
compositions
receptor agonists
Prior art date
Application number
MX2018012439A
Other languages
English (en)
Inventor
Solis Herrera Arturo
Original Assignee
Solis Herrera Arturo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016901359A external-priority patent/AU2016901359A0/en
Application filed by Solis Herrera Arturo filed Critical Solis Herrera Arturo
Publication of MX2018012439A publication Critical patent/MX2018012439A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0607—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities

Abstract

Se describen metodos de tratamiento y prevencion de condiciones de una membrana mucosa nasal o paranasal; los metodos incluyen administrar una composicion farmaceutica que incluye un agonista del receptor de acetilcolina de tipo nicotinico (nAChR), tal como (S)-(1-metil-2-pirrolidinil)-piridina, o una sal, analogo, precursor, o derivado farmaceuticamente aceptable del mismo; los metodos se pueden usar para tratar una amplia variedad de condiciones de la membrana mucosa nasal o paranasal, tal como congestion nasal y sangrados nasales.
MX2018012439A 2016-04-12 2017-04-12 Composiciones y metodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotinico. MX2018012439A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016901359A AU2016901359A0 (en) 2016-04-12 Application of Nicotine Compounds to Nasal Membranes
PCT/IB2017/000764 WO2017178897A2 (en) 2016-04-12 2017-04-12 Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
MX2018012439A true MX2018012439A (es) 2019-02-21

Family

ID=60042487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012439A MX2018012439A (es) 2016-04-12 2017-04-12 Composiciones y metodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotinico.

Country Status (13)

Country Link
US (1) US10639300B2 (es)
EP (1) EP3442583B1 (es)
JP (1) JP6770091B2 (es)
KR (1) KR102199560B1 (es)
CN (1) CN109069649A (es)
AU (1) AU2017250514B2 (es)
BR (2) BR122023020807A2 (es)
CA (1) CA3014725C (es)
HK (1) HK1258883A1 (es)
MX (1) MX2018012439A (es)
NZ (1) NZ744942A (es)
RU (1) RU2718061C1 (es)
WO (1) WO2017178897A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096932B2 (en) * 2016-09-29 2021-08-24 The Uab Research Foundation Methods and compositions for increasing mucus clearance

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8301659D0 (en) 1983-01-21 1983-02-23 Leo Ab Smoking substitutes
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
MA23588A1 (fr) * 1994-06-23 1995-12-31 Procter & Gamble Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6596740B2 (en) * 2000-10-24 2003-07-22 Richard L. Jones Nicotine mucosal spray
HU224941B1 (en) 2001-08-10 2006-04-28 Bgi Innovacios Kft Phototerapy apparatus
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
CN1735414A (zh) 2002-12-06 2006-02-15 北岸长岛犹太人研究学院 用α7受体结合类胆碱激动剂抑制炎症
PL1663168T3 (pl) 2003-09-08 2009-07-31 Mcneil Ab Preparaty nikotyny i ich zastosowanie
CN101001843B (zh) 2004-07-15 2014-08-27 拉瓦尔大学 用于治疗炎性疾病的烟碱受体激动剂
CN101437515B (zh) 2006-05-08 2016-04-20 阿图罗·索利斯埃雷拉 烟碱、其类似物、其前体或其衍生物用于通过以预防形式或治疗形式参与的α-MSH改善治疗各种病理过程的应用
WO2008062453A2 (en) * 2006-09-25 2008-05-29 Nikki Nikhilesh Singh Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US9744375B2 (en) * 2010-08-05 2017-08-29 Allergia, Inc. Apparatus and methods for controlling and applying flash lamp radiation
WO2015084544A1 (en) 2013-12-05 2015-06-11 Ploom, Inc. Nicotine liquid formulations for aerosol devices and methods thereof
CN104706556A (zh) 2015-03-31 2015-06-17 苏州维泰生物技术有限公司 抗过敏组合物及其在化妆品中的应用

Also Published As

Publication number Publication date
AU2017250514B2 (en) 2019-12-19
RU2718061C1 (ru) 2020-03-30
AU2017250514A1 (en) 2018-08-23
EP3442583B1 (en) 2024-04-10
EP3442583A4 (en) 2019-12-25
JP2019511520A (ja) 2019-04-25
CN109069649A (zh) 2018-12-21
BR112018067718A2 (pt) 2019-01-08
WO2017178897A2 (en) 2017-10-19
US20190111038A1 (en) 2019-04-18
JP6770091B2 (ja) 2020-10-14
CA3014725C (en) 2020-09-22
HK1258883A1 (zh) 2019-11-22
CA3014725A1 (en) 2017-10-19
BR122023020807A2 (pt) 2023-12-12
NZ744942A (en) 2020-08-28
WO2017178897A3 (en) 2017-11-23
EP3442583A2 (en) 2019-02-20
US10639300B2 (en) 2020-05-05
KR20180108821A (ko) 2018-10-04
KR102199560B1 (ko) 2021-01-07

Similar Documents

Publication Publication Date Title
NZ722927A (en) Aerosol pirfenidone and pyridone analog compounds and uses thereof
MD4539C1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
NZ724756A (en) An inhalable rapamycin formulation for treating age-related conditions
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
EA033113B1 (ru) Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
PH12017502087B1 (en) Tiotropium inhalation solution for nebulization
NZ705260A (en) Aerosol pirfenidone and pyridine analog compounds for the treatment of lung disease
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
ZA202212128B (en) Combination of alcaftadine and a corticosteroid
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.
MX2018012439A (es) Composiciones y metodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotinico.
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
PH12017501736A1 (en) Indole derivatives
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
WO2015130963A3 (en) Compositions and methods for administering insulin or insulin-like protein to the brain